ImKramer
Status: Living the HCV- Free life. S'awesome! :)
Mood:
Ok
Offline
- Gilead combo hepatitis C pill effective in small trialThu May 2, 2013 12:18pm EDT(Reuters) - Gilead Sciences Inc on Thursday said almost all patients taking a fixed-dose combination of two of its experimental hepatitis C drugs appeared to have...
- Beta-blockers reduced bacterial translocation, improved intestinal permeability in cirrhotic patientsMay 1, 2013Patients with cirrhosis treated with beta-blockers experienced improved intestinal permeability and reduced bacterial translocation,...
- Okay please don't shoot the messenger as I am only sharing important links to information about everything HCV. Good news and bad. I am sorry I do not write these, make them up. I have no agenda nor do I feel guilty of indulging in "scare tactics".I...
- Compassionate access to new hepatitis C drugs an "emergency" for European patientsDoctors, patients and regulators debate the risks and benefits of earlier access for the sickest patientsread...
- Galectin Therapeutics, Inc. (NASDAQ: GALT) Spikes on Positive Data from Cirrhosis StudyPosted on April 29, 2013 by EditorFollowing the release of positive data involving their drugs GR-MD-02 and GM-CT-01 that are intended to inhibit galectin...
- MONDAY, APRIL 29, 2013Hep C quad regimens quashed, but some components go forwardA pair of four-drug interferon-based hepatitis C regimens worked well, but further study has been halted after a few patients experienced serious adverse events,...
- BioLineRx Enrolls First Patient in Phase I/II Clinical Trial for BL-8020, an Oral, Interferon-Free Treatment for Hepatitis Chttp://www.biolinerx.com/default.asp?pageid=16&itemid=186
- Daclatasvir + sofosbuvir offers hepatitis C rescue therapy after current standard of careAn interferon-free regimen of daclatasvir plus sofosbuvir, with or without ribavirin, cured all previously treated hepatitis C (HCV) patients who did not...
- EASL 2013 Highlights - CCO's independent conference coverage.http://hepatitiscnewdrugs.blogspot.ca/2013/04/easl-2013-highlights-ccos-independent.html
- New Data from AbbVie's Phase IIb Aviator Trial Demonstrate High Sustained Viral Response Rates Across Multiple Patient Types with HCV Genotype 1 - press release EASL 48th Annual MeetingApril 24th - 28th 2013The Netherlands,...
- Idenix Reports Favorable Resistance Profile for IDX719, a Potent, Pan-Genotypic HCV NS5A Inhibitor, at EASL Meetinghttp://hcvadvocate.blogspot.ca/2013/04/idenix-reports-favorable-resistance.html
- AbbVie says drug cocktail wipes out hepatitis C in 8 weeksApril 23, 2013http://articles.chicagotribune.com/2013-04-23/business/chi-abbvie-hepatitis-c-drug-abbv-20130423_1_gilead-sciences-inc-gilead-drug-abbvie-inc
- Could we possibly see "off label" treatment for Geno1 by the end of this year?It may be possible as Simeprevir and Sofosbuvir are both at FDA for approval right now.Let's hope for the best!http://www.aidsmap.com/page/2597301/
- 25 Photos You Need To Really Look At To UnderstandEver notice how many things look like genitals at first glance?http://www.buzzfeed.com/awesomer/photos-you-really-need-to-look-at-to-understand
- If you are a member of Medscape you can view this press release for yourself.For those that are not members I copy/paste for your convenience.http://www.medscape.com/viewarticle/803129Oral Regimen Sustains Hepatitis C Viral Response to 24...